Reports Q4 revenue $29.5M, consensus $28.47.”We enter 2025 with positive momentum, having delivered two solid quarters under our transforming commercial organization,” said Leslie Trigg, Chair and Chief Executive Officer. “Strong utilization across our Tablo installed base drove another record quarter of recurring revenue, and our strengthened balance sheet positions us through cash flow breakeven. Our team remains focused on the opportunities ahead-supporting customers, restoring well-being to people with end-stage renal disease and driving meaningful growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- OM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outset Medical announces resolution of FDA warning letter
- Outset Medical files $100M mixed securities shelf
- Strategic Inventory Management and Operational Resilience Justify Buy Rating for Outset Medical
- Outset Medical price target lowered to $3 from $4 at BTIG